Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635

Biomea Fusion, Inc. (Nasdaq: BMEA) ("Biomea" or the "Company"), a clinical stage biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically defined cancers and metabolic diseases, today announced that on May 1, 2024, the compensation committee of Biomea's board of directors granted 8 new employees non-qualified stock options to purchase an aggregate of 80,250 shares of the Company's common stock. The shares underlying each employee's stock options will vest 116 on a quarterly basis over four years, in each case subject to each such employee's continued employment with the Company on such vesting dates. All of the above-described awards were made under Biomea's 2023 Inducement Equity Plan (the "Plan").

The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan. The Plan was adopted by Biomea's board of directors on November 17, 2023.

About Biomea Fusion

Biomea Fusion is a clinical stage biopharmaceutical company focused on the discovery and development of oral covalent small molecules to treat patients with metabolic diseases and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional non-covalent drugs, including greater target selectivity, lower drug exposure, and the ability to drive a deeper, more durable response.

We are utilizing our proprietary FUSION™ System to discover, design and develop a pipeline of next-generation covalent-binding small molecule medicines designed to maximize clinical benefit for patients with various cancers and metabolic diseases, including diabetes. We aim to have an outsized impact on the treatment of disease for the patients we serve. We aim to cure.

Visit us at biomeafusion.com and follow us on LinkedIn , Twitter and Facebook .


Contact: Investor Relations Chunyi Zhao, PhD Associate Director of Investor Relations & Corporate Development czhao@biomeafusion.com

Primary Logo

News Provided by GlobeNewswire via QuoteMedia

BMEA:US
The Conversation (0)
Biomea Fusion Announces BMF-219 in Diabetes Placed on Clinical Hold

Biomea Fusion Announces BMF-219 in Diabetes Placed on Clinical Hold

Biomea Fusion, Inc. ("Biomea" or the "Company") (Nasdaq: BMEA), announced that the Company has received notice from the U.S. Food and Drug Administration (FDA) that a full clinical hold has been placed on Biomea's ongoing Phase III clinical trials of the Company's investigational covalent menin... Keep Reading...
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635

Biomea Fusion, Inc. (Nasdaq: BMEA) ("Biomea" or the "Company"), a clinical stage biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically defined cancers and metabolic diseases, today announced that on June 1, 2024, the... Keep Reading...
Biomea Fusion Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes

Biomea Fusion Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes

Biomea Fusion, Inc. ("Biomea") (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with metabolic diseases and genetically defined cancers, today announced the completion of... Keep Reading...
Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights

Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights

Reported positive data from the escalation portion of Phase 1/2 study (COVALENT-111) in type 2 diabetes patients, displaying durable improved glycemic control while off therapy for 22 weeks, supporting the disease-modifying potential of BMF-219 to address a root cause of diabetes: a loss of... Keep Reading...
Canadian Investment Regulatory Organization Trade Resumption - ANK

Canadian Investment Regulatory Organization Trade Resumption - ANK

Trading resumes in: Company: Angkor Resources Corp. TSX-Venture Symbol: ANK All Issues: Yes Resumption (ET): 11:15 AM CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly... Keep Reading...
Angkor Resources Receives Preliminary Feedback on the First Basin of the Seismic Program with Enercam's Oil & Gas Block VIII, Cambodia

Angkor Resources Receives Preliminary Feedback on the First Basin of the Seismic Program with Enercam's Oil & Gas Block VIII, Cambodia

(TheNewswire) GRANDE PRAIRIE, ALBERTA TheNewswire - October 6, 2025 - Angkor Resources Corp. (TSXV: ANK,OTC:ANKOF) ("ANGKOR" OR "THE COMPANY") announces its subsidiary, EnerCam Resources Co. Ltd. (Cambodia) ("EnerCam") has reviewed preliminary data from South Bokor Basin from the 2-D seismic... Keep Reading...
Bold Ventures Discovers New Style of Mineralization on Its Wilcorp Property

Bold Ventures Discovers New Style of Mineralization on Its Wilcorp Property

Bold Ventures Inc. (TSXV: BOL,OTC:BVLDF) (the "Company" or "Bold") is pleased to announce the discovery of a new style of mineralization on its Wilcorp Property (the "Property") in the Atikokan area in Ontario, consisting of significant Au-Ag-Cu mineralization from sulphide-quartz stringers in... Keep Reading...
Finlay Minerals Announces Non-Brokered Private Placement of Flow-Through and Non-Flow-Through Units

Finlay Minerals Announces Non-Brokered Private Placement of Flow-Through and Non-Flow-Through Units

/NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES/ finlay minerals ltd. (TSXV: FYL,OTC:FYMNF) (OTCQB: FYMNF) ("Finlay" or the "Company") is pleased to announce that it intends to complete a non-brokered private placement (the " Private Placement ") consisting of the... Keep Reading...
Quetzal Announces Conditional Acceptance of Reverse Takeover And Filing Statement

Quetzal Announces Conditional Acceptance of Reverse Takeover And Filing Statement

Quetzal Copper Corp. (TSXV: Q,OTC:QTZCF) ("Quetzal") is pleased to announce that it has received conditional acceptance from the TSX Venture Exchange (the "Exchange") for its previously announced reverse takeover transaction (the "Transaction") with Silverco Mining Corp. ("Silverco") (see news... Keep Reading...
Questcorp Mining Provides Update on Private Placement

Questcorp Mining Provides Update on Private Placement

Questcorp Mining Inc. (CSE: QQQ,OTC:QQCMF) (OTCQB: QQCMF) (FSE: D910) (the "Company" or "Questcorp") announces that it has revised the terms of its previously announced non-brokered private placement (the "Offering"). The Company will now offer up to 7,500,000 units (each, an "AI Unit") at a... Keep Reading...

Latest Press Releases

Related News